Revolution Medicines Rallies as Daraxonrasib Shows Survival Benefit in Pancreatic Cancer Trial

Revolution Medicines Inc. (RVMD) shares surged on June 1, 2026, after the company reported that its experimental therapy daraxonrasib demonstrated a significant improvement in overall survival for patients with advanced pancreatic ductal adenocarcinoma in a late-stage clinical trial. The RAS(ON) inhibitor met its primary endpoint, extending median overall survival by a statistically meaningful margin compared to standard-of-care chemotherapy, according to company data. Detailed results, including specific survival figures and safety profiles, will be presented at an upcoming medical conference. Pancreatic cancer remains one of the deadliest malignancies with limited treatment options. Daraxonrasib targets RAS mutations, which are present in more than 90% of pancreatic cancer cases. The company plans to discuss the data with U.S. regulators and aims to submit a new drug application by late 2026.